Drug intelligence / Profile preview

sophoraflavanone G

Development stage
Preclinical
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
Administration
Experimental (intraperitoneal In Animal Studies), Topical, Oral (preclinical, Pk Modeling), Not Approved For Clinical Use
01

Overview

**Sophoraflavanone G** is a naturally occurring flavonoid compound isolated primarily from *Sophora flavescens* and other *Sophora* species. It is a plant-derived small molecule bearing antioxidant, anti-inflammatory, antitumor, and notable antimicrobial activities, especially against antibiotic-resistant bacteria. Mechanistically, sophoraflavanone G demonstrates anti-tumor activity via induction of apoptosis in cancer cells (e.g., triple-negative breast cancer and leukemia) mediated, at least in part, by suppression of MAPK-related pathways. In immune models, it attenuates airway hyper-responsiveness and inflammation likely by inhibiting Th2 cytokine secretion and reducing oxidative stress. Preclinical research also indicates synergism with several antibiotics, enhancing their effectivity against resistant bacterial strains. Although studied for diverse pharmacological activities, it is primarily used in research; there is no evidence of clinical approval as a pharmaceutical or dietary supplement[1][3][4][5][6][7].

Other names
kushenol Fnorkurarinonevexibinol(-)-vexibinolkushenin
02

Targets

TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)BACE1 (Beta-site APP-cleaving enzyme 1)PGHS-1 (Prostaglandin G/H Synthase 1)ESR1 (ERα)MEKSGLT2 (Sodium-glucose cotransporter protein subunit 2)

Beyond the preview

Go deeper on sophoraflavanone G.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on sophoraflavanone G.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call